Overview

3D011-08 Monotherapy in Subjects With Advanced Solid Tumors

Status:
Not yet recruiting
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is evaluate the the safety, tolerability, pharmacokinetics profiles, and preliminary efficacy of 3D011-08 in subjects with advanced solid tumors.
Phase:
Phase 1
Details
Lead Sponsor:
3D Medicines (Beijing) Co., Ltd.